Clinical Trial

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Not Yet Recruiting Phase 2

Record status

This record was last updated September 21, 2023 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC). It is mainly aimed at the population of patients with primary IIA- IIIA EGFR sensitive mutations that are intended to be treated with Osimertinib neoadjuvant therapy.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-08-27; most recent amendment 2023-09-16.

Trial Details

NCT Number	NCT06018688
Lead Sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions	Non Small Cell Lung Cancer, EGFR Gene Mutation
Enrollment	44 participants
Start Date	2023-09-15
Primary Completion	2026-03-01 (estimated)
Study Completion	2026-09-01 (estimated)
Updated on ClinicalTrials.gov	2023-09-21